Valuation & Return Analysis
Where the market is paying up — and why. Multiples, quality-vs-valuation positioning and long-run shareholder returns across the Indian pharma universe.
How expensive each company's stock is, and how much money shareholders actually made — plus why the winners won. Valuation 'multiples' tell you what the market is willing to pay.
The scatter plots quality (ROCE) against price (P/E) — top-left is cheap-and-good, top-right is expensive. The table lists every multiple and 1/3/5/10-year returns. The bottom panel explains the recurring drivers of long-run returns.
- P/E
- — Price ÷ annual earnings per share. ~20× is average; >40× prices in high growth.
- EV/EBITDA
- — A debt-aware valuation multiple — useful for comparing companies with different leverage.
- P/B
- — Price ÷ book value (net assets). High for asset-light, high-return businesses.
- Return attribution
- — Splitting a stock's return into earnings growth vs. valuation re-rating vs. dividends.
Quality vs Valuation
ROCE × P/E · bubble = market cap · Rubicon highlighted
High-ROCE brand-led compounders (Abbott, GSK, Torrent, Ajanta) command premium multiples; US-generic-heavy names (Aurobindo, Alembic) trade cheaper on regulatory & erosion risk.
Valuation & Returns Table
Multiples and trailing shareholder returns (illustrative)
| Company | Mkt cap | P/E | EV/EBITDA | P/B | 1Y | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹4.3L Cr | 35x | 27.0x | 5.7x | +9% | +30% | +22% | +8% |
| Divi's Laboratories | ₹1.8L Cr | 68x | 42.0x | 10.6x | +3% | +23% | +10% | +20% |
| Torrent Pharmaceuticals | ₹1.5L Cr | 68x | 42.0x | 17.9x | +37% | +34% | +25% | +21% |
| Cipla | ₹1.1L Cr | 29x | 15.0x | 3.2x | -9% | +15% | +7% | +11% |
| Zydus Lifesciences | ₹1.1L Cr | 20x | 13.0x | 3.9x | +13% | +25% | +12% | +9% |
| Dr. Reddy's Laboratories | ₹1.1L Cr | 25x | 13.0x | 2.8x | -3% | +9% | +4% | +8% |
| Lupin | ₹1.0L Cr | 18x | 12.0x | 4.6x | +17% | +40% | +25% | +5% |
| Mankind Pharma | ₹98.1K Cr | 49x | 30.0x | 6.0x | — | +13% | — | — |
| Aurobindo Pharma | ₹82.7K Cr | 23x | 11.0x | 2.2x | +26% | +27% | +8% | +7% |
| Laurus Labs | ₹74.2K Cr | 83x | 30.0x | 13.9x | +108% | +55% | +18% | — |
| Biocon | ₹66.6K Cr | 171x | 16.0x | 2.0x | +18% | +19% | +1% | +13% |
| Alkem Laboratories | ₹64.0K Cr | 26x | 18.0x | 4.6x | +11% | +16% | +11% | +14% |
| Abbott India | ₹55.3K Cr | 36x | 28.0x | 11.6x | -18% | +5% | +10% | +20% |
| Ajanta Pharma | ₹38.4K Cr | 36x | 26.0x | 8.5x | +21% | +28% | +19% | +12% |
| GSK Pharmaceuticals (India) | ₹36.8K Cr | 38x | 35.0x | 16.3x | -32% | +16% | +8% | +2% |
| J.B. Chemicals & Pharmaceuticals | ₹35.1K Cr | 49x | 28.0x | 8.5x | +27% | +25% | +23% | +34% |
| Piramal Pharma | ₹21.9K Cr | 110x | 18.0x | 2.7x | -16% | +21% | — | — |
| Neuland Laboratories | ₹21.7K Cr | 60x | 35.0x | 11.5x | +33% | +79% | +53% | +36% |
| Rubicon Research | ₹21.1K Cr | 104x | 55.0x | 12.0x | — | — | — | — |
| Pfizer (India) | ₹20.7K Cr | 27x | 28.0x | 4.9x | -23% | +5% | -4% | +9% |
| Eris Lifesciences | ₹19.5K Cr | 31x | 19.0x | 5.0x | -23% | +28% | +14% | — |
| Granules India | ₹18.6K Cr | 31x | 14.0x | 3.7x | +50% | +37% | +19% | +18% |
| Syngene International | ₹18.1K Cr | 48x | 17.0x | 3.8x | -30% | -15% | -5% | +9% |
| Caplin Point Laboratories | ₹17.8K Cr | 28x | 22.0x | 5.0x | +14% | +43% | +29% | +29% |
| Suven Pharmaceuticals (now Cohance Lifesciences) | ₹16.5K Cr | 83x | 35.0x | 4.2x | -57% | -4% | -2% | — |
| Alembic Pharmaceuticals | ₹14.7K Cr | 20x | 16.0x | 2.6x | -23% | +7% | -5% | +4% |
Why the value creators outperformed
Return attribution — the recurring pattern
Most of the 5-10Y return came from compounding revenue × margin × mix, not multiples. Brand-led chronic and complex-generic names led.
Quality franchises (Torrent, Ajanta, Mankind) re-rated as the market paid for durable ROCE and chronic mix.
The laggards were hit by USFDA actions and US price erosion — capital destruction, not just slow growth.